Liu Ao, Zhao Yandong, Qiu Tong, Xuan Yunpeng, Qin Yi, Sun Xiao, Xu Rongjian, Du Wenxing, Wu Zhe, Veronesi Giulia, Amore Dario, Jiao Wenjie
Department of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Faculty of Medicine and Surgery, Vita-Salute San Raffaele University, Milan, Italy.
Transl Lung Cancer Res. 2022 May;11(5):869-879. doi: 10.21037/tlcr-22-298.
Up to now, no study has described the long-term survival and its prognostic factors of robot-assisted sleeve lobectomy. Here, the present cohort study reported the long-term oncologic outcomes of robot-assisted sleeve lobectomy to evaluate the oncological feasibility of sleeve lobectomy via a robotic surgical system in patients with centrally located non-small cell lung cancer (NSCLC).
A total of 104 consecutive patients with centrally located NSCLC who underwent robot-assisted bronchial single sleeve lobectomy between October 2014 and May 2021 were retrospectively reviewed. Bronchial single sleeve lobectomy only refers to the resection and end-to-end anastomosis reconstruction of the bronchus, without the resection of the pulmonary vessels or carina. The recurrence status during follow-up, 5-year overall survival (OS) and disease-free survival (DFS) were assessed.
In the total cohort, 47 (45.2%) patients had pathological stage I disease, 28 (26.9%) patients had pathological stage II disease, and 29 (27.9%) patients had pathological stage III disease. Recurrence occurred in 26 (25.0%) patients, including locoregional recurrence in 10 (9.6%) patients and distant recurrence in 16 (15.4%) patients. No endobronchial nor perianastomotic recurrence was detected. The Kaplan-Meier curves indicated that the 5-year DFS and OS rates in the cohort were 67.9% and 73.0%, respectively. In terms of pathological stages, the 5-year DFS and OS rates were 82.9% and 82.2% for stage I patients, 57.8% and 69.7% for stage II patients, and 54.5% and 63.7% for stage III patients, respectively. Multivariable analyses demonstrated that higher pathological stage or N2 stage were independent risk factors for poorer DFS and OS.
Robot-assisted bronchial single sleeve lobectomy could be an oncologically adequate procedure for patients with centrally located NSCLC, due to the long-term survival was similar to that reported for video-assisted thoracoscopic surgery (VATS) or open technique. Further studies of comparative studies or high-quality randomized controlled trials are required.
迄今为止,尚无研究描述机器人辅助袖状肺叶切除术的长期生存情况及其预后因素。在此,本队列研究报告了机器人辅助袖状肺叶切除术的长期肿瘤学结局,以评估通过机器人手术系统行袖状肺叶切除术治疗中央型非小细胞肺癌(NSCLC)患者的肿瘤学可行性。
回顾性分析了2014年10月至2021年5月期间连续接受机器人辅助支气管单袖状肺叶切除术的104例中央型NSCLC患者。支气管单袖状肺叶切除术仅指支气管的切除及端端吻合重建,不包括肺血管或隆突的切除。评估随访期间的复发情况、5年总生存率(OS)和无病生存率(DFS)。
在整个队列中,47例(45.2%)患者为病理I期疾病,28例(26.9%)患者为病理II期疾病,29例(27.9%)患者为病理III期疾病。26例(25.0%)患者出现复发,包括10例(9.6%)患者局部区域复发和16例(15.4%)患者远处复发。未检测到支气管内或吻合口周围复发。Kaplan-Meier曲线显示,该队列的5年DFS率和OS率分别为67.9%和73.0%。就病理分期而言,I期患者的5年DFS率和OS率分别为82.9%和82.2%,II期患者分别为57.8%和69.7%,III期患者分别为54.5%和63.7%。多变量分析表明,较高的病理分期或N2期是DFS和OS较差的独立危险因素。
机器人辅助支气管单袖状肺叶切除术对于中央型NSCLC患者可能是一种肿瘤学上合适的手术方法,因为其长期生存率与电视辅助胸腔镜手术(VATS)或开放手术报道的相似。需要进一步开展比较研究或高质量随机对照试验。